Key Points
- Jennifer Michaelson sold 2,898 shares of Cullinan Therapeutics on Dec. 18 at an average price of $9.67 for $28,023.66, cutting her stake by 2.12% to 133,980 shares valued at about $1.30M.
- The Dec. 18 sale is part of a recent series of insider disposals—she sold 995 shares on Dec. 15, 2,148 on Dec. 12 and 4,000 on Nov. 24—totaling 10,041 shares sold in Nov–Dec.
- Cullinan shares opened at $9.68 (down ~3%), trade in a 12‑month range of $5.68–$13.33 with a $571.9M market cap, and carry a consensus "Moderate Buy" analyst rating with an average price target of $28.29 amid mixed research notes.
Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) insider Jennifer Michaelson sold 2,898 shares of Cullinan Therapeutics stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $9.67, for a total value of $28,023.66. Following the completion of the sale, the insider owned 133,980 shares of the company's stock, valued at $1,295,586.60. The trade was a 2.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Jennifer Michaelson also recently made the following trade(s):
- On Monday, December 15th, Jennifer Michaelson sold 995 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $11.90, for a total transaction of $11,840.50.
- On Friday, December 12th, Jennifer Michaelson sold 2,148 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $12.38, for a total transaction of $26,592.24.
- On Monday, November 24th, Jennifer Michaelson sold 4,000 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $12.30, for a total value of $49,200.00.
Cullinan Therapeutics Stock Down 3.0%
Shares of NASDAQ:CGEM opened at $9.68 on Friday. Cullinan Therapeutics, Inc. has a twelve month low of $5.68 and a twelve month high of $13.33. The stock has a market capitalization of $571.89 million, a PE ratio of -2.92 and a beta of -0.10. The firm's 50 day moving average price is $9.35 and its 200-day moving average price is $8.12.
Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.77) earnings per share for the quarter, topping the consensus estimate of ($0.95) by $0.18. Analysts expect that Cullinan Therapeutics, Inc. will post -3.04 earnings per share for the current fiscal year.
Analyst Ratings Changes
CGEM has been the topic of several research analyst reports. BTIG Research boosted their price objective on Cullinan Therapeutics from $32.00 to $38.00 and gave the company a "buy" rating in a research report on Monday, November 24th. Weiss Ratings reissued a "sell (d-)" rating on shares of Cullinan Therapeutics in a research note on Monday, December 8th. Zacks Research raised Cullinan Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Tuesday, September 16th. New Street Research set a $26.00 price target on Cullinan Therapeutics in a report on Thursday, November 20th. Finally, Wedbush lifted their price objective on shares of Cullinan Therapeutics from $25.00 to $34.00 and gave the stock an "outperform" rating in a research note on Tuesday, December 9th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $28.29.
View Our Latest Research Report on CGEM
Institutional Investors Weigh In On Cullinan Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of CGEM. Rafferty Asset Management LLC lifted its stake in shares of Cullinan Therapeutics by 3.8% during the 3rd quarter. Rafferty Asset Management LLC now owns 40,729 shares of the company's stock worth $242,000 after acquiring an additional 1,503 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in Cullinan Therapeutics by 44.6% in the second quarter. Tower Research Capital LLC TRC now owns 8,182 shares of the company's stock worth $62,000 after purchasing an additional 2,523 shares during the period. Rhumbline Advisers lifted its position in shares of Cullinan Therapeutics by 3.9% during the second quarter. Rhumbline Advisers now owns 74,105 shares of the company's stock worth $558,000 after purchasing an additional 2,767 shares during the last quarter. Tema Etfs LLC boosted its stake in shares of Cullinan Therapeutics by 9.0% during the second quarter. Tema Etfs LLC now owns 42,692 shares of the company's stock valued at $321,000 after purchasing an additional 3,528 shares during the period. Finally, Brooklyn Investment Group bought a new position in shares of Cullinan Therapeutics in the first quarter worth about $34,000. 86.31% of the stock is currently owned by hedge funds and other institutional investors.
Cullinan Therapeutics Company Profile
(
Get Free Report)
Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
